Cancer Overview Increasing Collaboration to Accommodate Increasing Fragmentation

Introduction

The global cancer market is predicted to be worth around $20 billion in 2003, and is expected to increase to over $45 billion by 2011. Over the next decade, advances in the pharmacotherapy of cancer will come not only from improvements in the traditional classes of therapies, but also from introduction of innovative therapies that display improved efficacy and toxicity through a targeted approach.

Scope

Patient potential of the ten major tumor types, including key trends in their epidemiology and reviews of their current treatment methods 

Data for the following cancers: breast, prostate, lung, colorectal, ovarian, brain, pancreatic, head and neck, leukemia and malignant melanoma 

Company oncology pipeline analysis of Aventis, Roche, and Bristol-Myers Squibb 

Analysis of the phase III drugs, including clinical trial data and descriptions of their market potential, with sales forecasts to 2011 for key drugs 

Report Highlights

Datamonitor predicts that the 10 major tumor types covered in this report will be responsible for the deaths of over 1.25 million people in 2003 within the seven major markets. The size of the cancer problem is reflected by the size of the global cancer market, which is predicted to be worth around $20 billion in 2003. 

The traditional treatment classes including cytotoxic and hormonal therapies will continue to form the backbone of standard cancer therapy, and hence should continue to achieve strong sales in the short-term. 

Reasons to Purchase

Assess competitive threat from novel compounds entering the cancer market 

Characterize saturated and under-served markets in cancer 

Find potential out-licensing and co-marketing partners in the cancer market 

Report Highlights

The cancer market will see continued strong growth of the innovatives classes of therapies. Pharmaceutical companies should invest in the development or in-licensing of innovative cancer treatments to maintain market share. The key to the success of an innovative therapy is synergy with traditional therapies. 

November 2003, 205 pages

Publisher: Datamonitor Oncology Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a216